Emerging options in the management of advanced intraocular retinoblastoma

British Journal of Ophthalmology

Volumn 93, Issue 7, 2009, Pages 848-849

  Honavar, Santosh G ^a  

^a L V PRASAD EYE INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; VINCRISTINE;

BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; EDITORIAL; ENUCLEATION; EXTERNAL BEAM RADIOTHERAPY; HUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; VISION;

EYE ENUCLEATION; HUMANS; RETINAL NEOPLASMS; RETINOBLASTOMA; VISUAL ACUITY;

EID: 67649635043     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2008.154427     Document Type: Editorial

References (26)

1. Shields JA, Shields CL, Sivalingam V. Decreasing frequency of enucleation in patients with retinoblastoma. Am J Ophthalmol 1989;108:185-188 (Pubitemid 19197953)
2. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction in unilateral retinoblastoma. Arch Ophthalmol 2002;120:1653-1658 (Pubitemid 36401799)
3. Epstein JA, Shields CL, Shields JA. Trends in the management of retinoblastoma: evaluation of 1,196 consecutive eyes during 1974 to 2001. J Pediatr Ophthalmol Strabismus 2003;40:196-203.
4. Berman EL, Donaldson CE, Giblin M, et al. Outcomes in retinoblastoma, 1974-2005: the Children's Hospital, Westmead. Clin Exp Ophthalmol 2007;35:5-12.
5. Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009;93:24-27
6. Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996;114:1339-1347 (Pubitemid 26398719)
7. Murphree AL, Villablanca JG, Deegan WF III, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-1356 (Pubitemid 26398720)
8. Shields CL, DePotter P, Himmelstein B, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-1338 (Pubitemid 26398718)
9. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002;133:657-664 (Pubitemid 34462014)
10. Shields CL, Honavar SG, Shields JA, et al. Factors predictive of recurrence of retinal tumor, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460-464 (Pubitemid 34727817)
11. Cohen VML, Kingston J, Hungerford JL. The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol 2009;93:887-890
12. Chan MPY, Hungerford JL, Kingston JE, et al. Salvage external beam radiotherapy after primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol 2009;93:891-894
13. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005;23:2272-2279 (Pubitemid 46218720)
14. Reddy VA, Honavar SG, Shome D, et al. Demographics, clinical profile, management and outcome of retinoblastoma. J Clin Oncol 2008;26(Suppl):10051.
15. Honavar SG, Shome D, Reddy VAP. Periocular carboplatin in the management of advanced intraocular retinoblastoma. Proceedings of the XII International Congress of Ocular Oncology, Vancouver, Canada, 2005.
16. Abramson DH, Frank CM, Dunkel IJ. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 1999;106:1947-1950
17. Schmack I, Hubbard GB, Kang SJ, et al. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. Am J Ophthalmol 2006;142:310-315 (Pubitemid 44131450)
18. Mulvihill A, Budning A, Jay V, et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch Ophthalmol 2003;121:1120-1124 (Pubitemid 36962165)
19. Van Quill KR, Dioguardi PK, Tong CT, et al. Subconjunctival carboplatin in fibrin sealant in the treatment of transgenic murine retinoblastoma. Ophthalmology 2005;112:1151-1158 (Pubitemid 40797475)
20. Shome D, Bellare J, Sheorey U, et al. Does a nanomolecule of carboplatin injected periocularly help in attaining higher intravitreal concentrations? Proceedings of the Annual Meeting of the American Academy of Ophthalmology, New Orleans, 2007:391.
21. Meadows AT, Chintagumpala M, Dunkel IJ, et al. Children's Oncology Group (COG) Trials for Retinoblastoma. In: Singh AD, Damato BE, Pe'er J, et al., eds. Clinical Ophthalmic Oncology. Philadelphia: Saunders-Elsevier, 2007:491-495
22. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 2007;114:1378-1383
23. Seregard S, Kock E, af Trampe E. Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. Br J Ophthalmol 1995;79:194-195
24. Reese AB, Hyman G, Tapley N, et al. The treatment of retinoblastoma by X-ray and triethylene melamine. AMA Arch Ophthalmol 1958;60:897-906.
25. Suzuki S, Kaneko A. management of intraocular retinoblastoma and ocular prognosis. Int J Clin Oncol 2004;9:1-6. (Pubitemid 38470656)
26. Abramson DH, Dunkel IJ, Brodie SE, et al. A phase I/ II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma-initial results. Ophthalmology 2008;115:1398-1404